登录

Daxiang Tech Raises ¥10M in Series A Funding Round

作者: Mailman 2021-06-08 23:29
大橡科技
https://www.daxiangbio.com
企业数据由 动脉橙 提供支持
人体器官芯片和类器官芯片研发、生产商 | PreB轮 | 运营中
中国-北京
2022-11-14
融资金额:近亿人民币
比邻星创投
查看

(VCBeat) May. 11, 2021 -- Beijing Daxiang Technology Co., Ltd. ("Daxiang Tech"), a leader in the field of organ-on-chips (OOC) in China, has raised tens of millions in a Series A financing round, led by CDH VGC, with participation from Miracle Plus and the existing investors including WuXi AppTec, Furong Capital and Jiuyou Capital.


Zhou Yu, CEO of Daxiang Tech, revealed that this round of financing will mainly be used to accelerate the construction of its existing OOC industrial chain as well as the research and development of new OOC and model, to provide high bionic and high-throughput tools for innovative drug discovery and development, and improve the efficiency of drug R&D. At the same time, Daxiang Tech will promote the application of OOC in the field of personalized precision medicine.


The so-called OOC technology is a perfect combination of microfluidic technology and tissue engineering, which can accurately control a variety of parameters, such as fluid shear force, molecular concentration gradient and multi-organ interaction, and can truly simulate the complex structure of human organs, tissue microenvironment and various physiological functions in vitro. At the World Economic Forum in Davos 2016, OOC was named one of the top 10 emerging technologies.


In August 2020, Daxiang Tech launched 3 types of OOC with completely independent intellectual property rights and built a variety of pathological and physiological models on this basis.


At present, relevant highly bionic models, such as the liver model, tumor model and blood-brain barrier model, have been verified by third-party authorities, and have been recognized by international pharmaceutical enterprises. As a result, Daxiang Tech has become the first OOC company in China to cooperate with top multinational pharmaceutical companies in drug R&D projects, realizing the business closed loop from technology platform, product R&D, industrial production to product application.


>>>>

About CDH VGC


Established in 2002, CDH is one of the leading alternative investment fund managers focused on China today with over US$19 billion of assets under management, as of February 31, 2020. From its roots in private equity, CDH has expanded to become a diversified alternative asset management platform covering: Private Equity, Real Assets, Venture and Growth Capital, Mezzanine & Credit, Public Equities and Wealth Management. CDH VGC focuses on investments in healthcare, TMT and other emerging industries with Chinese characteristics.


>>>>

About WuXi AppTec


WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. 


With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

汉赞迪品牌升级视频发布,“CANTUS FLEX 以心声·致新生”

埃微健康:打造医疗级智能手环手表,为3.3亿心血管病人提供院外监测解决方案

Laminate Medical获1200万美元融资,研发与生产医疗透析设备以治疗肾衰竭患者

或将改写人类健康的技术!Medgadget评选出年度最佳医用新科技

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Aidite Secures ¥100 Million in New Funding Round

2021-06-08
下一篇

Zhenyi Medical Announces Completion of ¥100 Million Series A Funding Round

2021-06-08